Secondary analysis of the phase III AENEAS trial: in 106 patients with untreated EGFR-mutated advanced NSCLC and baseline CNS metastases, aumolertinib prolonged median CNS PFS vs gefitinib (29.0 vs 8.3 months; HR 0.31). No new safety findings.
Secondary analysisn = 106
Lu et al. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)